Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma
The cost-effectiveness of high-dose chemotherapy in multiple myeloma was considered as part of a UK National Health Service Executive regional evidence-based appraisal process. The use of high-dose chemotherapy supported by autologous stem cell transplantation in patients under 65 years of age was shown to provide a marginal benefit of 0.7 life-years over conventional chemotherapy. This corresponded to an incremental cost 'per life-year gained' figure of approximately pound15 000, based upon initial treatment costs and trial-period data only. The use of high-dose chemotherapy in the first-line treatment of advanced multiple myeloma improves event-free and overall survival and appears to be a cost-effective treatment option
Sampson, FC., Beard, S., Scott, F., & Vandenberghe, E. (2001). Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. British Journal of Haematology, 113(4), 1015-1019.